European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment-Update 2023.

Autor: Stratigos AJ; First Department of Dermatology-Venereology, National and Kapodistrian University of Athens, Andreas Sygros Hospital, Athens, Greece. Electronic address: alstrat2@gmail.com., Garbe C; Centre for Dermatooncology, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany., Dessinioti C; First Department of Dermatology-Venereology, National and Kapodistrian University of Athens, Andreas Sygros Hospital, Athens, Greece., Lebbe C; Université Paris Cite, Dermato-Oncology AP-HP Hôpital Saint Louis, Cancer Institute APHP. Nord-Université Paris Cite, INSERM U976, Paris, France., van Akkooi A; Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia; Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia; Melanoma Institute Australia, Sydney, New South Wales, Australia., Bataille V; Mount Vernon Cancer Centre, East and North NHS Trust, Northwood, UK., Bastholt L; Department of Oncology, Odense University Hospital, Odense, Denmark., Dreno B; Nantes Université, INSERM, CNRS, Immunology and New Concepts in ImmunoTherapy, INCIT, UMR 1302/EMR6001, Nantes, France., Dummer R; Skin Cancer Centre at University Hospital, Zurich, Switzerland., Fargnoli MC; Dermatology Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy., Forsea AM; Carol Davila University of Medicine and Pharmacy Bucharest, Department of Oncologic Dermatology, Elias University Hospital Bucharest, Bucharest, Romania., Harwood CA; Centre for Cell Biology and Cutaneous Research, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK., Hauschild A; Department of Dermatology, University Hospital (UKSH), Kiel, Germany., Hoeller C; Department of Dermatology, Medical University of Vienna, Vienna, Austria., Kandolf-Sekulovic L; Department of Dermatology, Medical Faculty, Military Medical Academy, Belgrade, Serbia., Kaufmann R; Department of Dermatology, Venereology and Allergology, Frankfurt University Hospital, Frankfurt, Germany., Kelleners-Smeets NW; GROW-School for Oncology and Reproduction, Maastricht University, Maastricht, the Netherlands; Department of Dermatology, Maastricht University Medical Centre+, Maastricht University, Maastricht, the Netherlands., Lallas A; First Department of Dermatology, Aristotle University, Thessaloniki, Greece., Leiter U; Centre for Dermatooncology, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany., Malvehy J; Dermatology Department of Hospital Clinic of Barcelona, University of Barcelona, IDIBAPS, CIBER de enfermedades raras, Instituto Carlos III, Barcelona, Spain., Del Marmol V; Department of Dermatology, University Hospital Erasme, Université Libre de Bruxelles, Brussels, Belgium., Moreno-Ramirez D; Department of Medical and Surgical Dermatology Service, Hospital Universitario Virgen Macarena, Sevilla, Spain., Pellacani G; Dermatology Unit, University of Rome La Sapienza, Rome, Italy., Peris K; UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche Addominali ed Endocrino Metaboliche, Fondazione Policlinico Universitario A. Gemelli-IRCCS, Rome, Italy; Dermatologia, Università Cattolica del Sacro Cuore, Rome, Italy., Saiag P; Department of General and Oncologic Dermatology, Ambroise-Paré hospital, APHP, and EA 4340 'Biomarkers in Cancerology and Hemato-oncology', UVSQ, Université Paris-Saclay, Boulogne-Billancourt, France., Tagliaferri L; UOC Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A, Gemelli IRCCS, Rome, Italy., Trakatelli M; Department of Dermatology, Papageorgiou Hospital, Aristotle University Department of Medicine, Thessaloniki, Greece., Ioannides D; First Department of Dermatology, Aristotle University, Thessaloniki, Greece., Vieira R; Department of Dermatology, Coimbra Hospital and University Centre, Coimbra, Portugal., Zalaudek I; Department of Dermatology, University of Trieste, Trieste, Italy., Arenberger P; Department of Dermatovenereology, Third Faculty of Medicine, Charles University, Prague, Czech Republic., Eggermont AMM; University Medical Center Utrecht and Princess Máxima Center, Utrecht, the Netherlands; Comprehensive Cancer Center Munich, Technical University Munich and Ludwig Maximilian University, Munich, Germany., Röcken M; Centre for Dermatooncology, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany., Grob JJ; Aix Marseille University, APHM Hospital, Marseille, France., Lorigan P; Division of Cancer Sciences, University of Manchester, Manchester, UK; Department of Medical Oncology, Christie NHS Foundation Trust, Manchester, UK.
Jazyk: angličtina
Zdroj: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2023 Nov; Vol. 193, pp. 113252. Date of Electronic Publication: 2023 Jul 28.
DOI: 10.1016/j.ejca.2023.113252
Abstrakt: In order to update recommendations on treatment, supportive care, education, and follow-up of patients with invasive cutaneous squamous cell carcinoma (cSCC), a multidisciplinary panel of experts from the European Association of Dermato-Oncology (EADO), the European Dermatology Forum (EDF), the European Society for Radiotherapy and Oncology (ESTRO), the European Union of Medical Specialists (UEMS), the European Academy of Dermatology and Venereology (EADV), and the European Organisation of Research and Treatment of Cancer (EORTC) was formed. Recommendations were based on an evidence-based literature review, guidelines, and expert consensus. Treatment recommendations are presented for common primary cSCC (low risk, high risk), locally advanced cSCC, regional metastatic cSCC (operable or inoperable), and distant metastatic cSCC. For common primary cSCC, the first-line treatment is surgical excision with postoperative margin assessment or micrographically controlled surgery. Achieving clear surgical margins is the most important treatment consideration for patients with cSCCs amenable to surgery. Regarding adjuvant radiotherapy for patients with high-risk localised cSCC with clear surgical margins, current evidence has not shown significant benefit for those with at least one high-risk factor. Radiotherapy should be considered as the primary treatment for non-surgical candidates/tumours. For cSCC with cytologically or histologically confirmed regional nodal metastasis, lymph node dissection is recommended. For patients with metastatic or locally advanced cSCC who are not candidates for curative surgery or radiotherapy, anti-PD-1 agents are the first-line systemic treatment, with cemiplimab being the first approved systemic agent for advanced cSCC by the Food and Drugs Administration/European Medicines Agency. Second-line systemic treatments for advanced cSCC, include epidermal growth factor receptor inhibitors (cetuximab) combined with chemotherapy or radiotherapy. Multidisciplinary board decisions are mandatory for all patients with advanced cSCC, considering the risks of toxicity, the age and frailty of patients, and co-morbidities, including immunosuppression. Patients should be engaged in informed, shared decision-making on management and be provided with the best supportive care to improve symptom management and quality of life. The frequency of follow-up visits and investigations for subsequent new cSCC depends on underlying risk characteristics.
Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:
(Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: